Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Angiotensin II type 1 receptor (AT1R) is responsible for cardiovascular effects mediated by angiotensin II. This study aimed to investigate the impact of antibodies directed against AT1R (anti-AT1R) in renal allograft rejection. Methods: We evaluated 53 patients who had biopsy-proven rejection including antibody-mediated rejection (AMR) (N=22), T-cell-mediated rejection (TCMR) (N=29), and mixed AMR and TCMR (N=2). Donor specific HLA antibodies (DSA) and anti-AT1Rs were simultaneously determined. Results: Anti-AT1Rs were detected in 9.4% (5/53) of rejection patients (one with acute AMR, two with chronic active AMR, one with acute TCMR, and one with mixed acute AMR & TCMR). HLA antibodies and DSA were detected in 75.5% (40/53) and 49.1% (26/53) of patients, respectively. There was no significant difference in transplant characteristics between anti-AT1R(+) and anti-AT1R(-) patients except for the association of HLA class-I DSA(+) and anti-AT1R(+). Four of five anti-AT1R(+) patients had DSA and were also found to have AMR. A single anti-AT1R(+)/DSA(-) patient developed acute TCMR. Detection rates of DSA, HLA antibodies, or anti-AT1R were not different between AMR and TCMR. However, DSA(+)/anti-AT1R(+) was more frequently found in AMR than in TCMR (P=0.036). Patients with anti-AT1R showed a greater tendency to develop high-grade rejection as Banff IIA/IIB or AMR. Conclusions: The presence of anti-AT1R was significantly associated with HLA class-I DSA in renal allograft rejection patients. Both anti-AT1R and DSA positivity was associated with AMR in patients with renal allograft rejection.
Abstract
Background: Angiotensin II type 1 receptor (AT1R) is responsible for cardiovascular effects mediated by angiotensin II. This study aimed to investigate the impact of antibodies directed against AT1R (anti-AT1R) in renal allograft rejection. Methods: We evaluated 53 patients who had biopsy-proven rejection including antibody-mediated rejection (AMR) (N=22), T-cell-mediated rejection (TCMR) (N=29), and mixed AMR and TCMR (N=2). Donor specific HLA antibodies (DSA) and anti-AT1Rs were simultaneously determined. Results: Anti-AT1Rs were detected in 9.4% (5/53) of rejection patients (one with acute AMR, two with chronic active AMR, one with acute TCMR, and one with mixed acute AMR & TCMR). HLA antibodies and DSA were detected in 75.5% (40/53) and 49.1% (26/53) of patients, respectively. There was no significant difference in transplant characteristics between anti-AT1R(+) and anti-AT1R(-) patients except for the association of HLA class-I DSA(+) and anti-AT1R(+). Four of five anti-AT1R(+) patients had DSA and were also found to have AMR. A single anti-AT1R(+)/DSA(-) patient developed acute TCMR. Detection rates of DSA, HLA antibodies, or anti-AT1R were not different between AMR and TCMR. However, DSA(+)/anti-AT1R(+) was more frequently found in AMR than in TCMR (P=0.036). Patients with anti-AT1R showed a greater tendency to develop high-grade rejection as Banff IIA/IIB or AMR. Conclusions: The presence of anti-AT1R was significantly associated with HLA class-I DSA in renal allograft rejection patients. Both anti-AT1R and DSA positivity was associated with AMR in patients with renal allograft rejection.
참고문헌 (19)
- Giral M, "Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss", Am J Transplant, 13, pp.2567~2576 (2013)
- Cox ST, "Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation", Hum Immunol, 72, pp.827~834 (2011)
- Banasik M, "The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes", Transpl Int, 27, pp.1029~1038 (2014)
- Reinsmoen NL, "Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation", Hum Immunol, 74, pp.1474~1477 (2013)
- Dragun D, "Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection", N Engl J Med, 352, pp.558~569 (2005)
- Reinsmoen NL, "Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients", Transplantation, 90, pp.1473~1477 (2010)
- Taniguchi M, "Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies", Am J Transplant, 13, pp.2577~2589 (2013)
- Kelsch R, "Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II", Transplantation, 92, pp.e57~59 (2011)
- Chung BH, "Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy", Transpl Int, 27, pp.49~59 (2014)
- Kim Y, "Pretransplant IFN-γ ELISPOT assay as a potential screening test to select immunosuppression protocols for patients receiving basiliximab induction therapy.", Transl Res, 160, pp.230~236 (2012)
- 장지영, "Application of Calculated Panel Reactive Antibody Using HLA Frequencies in Koreans", Annals of Laboratory Medicine, 32(1), pp.66~72 (2012), 대한진단검사의학회
- 정혜윤, "Allelic and Haplotypic Diversity of HLA-A, -B, -C, and -DRB1 Genes in Koreans Defined by High-resolution DNA Typing", Annals of Laboratory Medicine, 30(6), pp.685~696 (2010), 대한진단검사의학회
- Solez K, "Banff 07 classification of renal allograft pathology: updates and future directions", Am J Transplant, 8, pp.753~760 (2008)
- Amico P, "Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies", Transplantation, 85, pp.1557~1563 (2008)
- Reinsmoen NL, "Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome", Transplantation, 97, pp.595~601 (2014)
- Martin L, "Detection of donor-specific anti-HLA antibodies with flow cytometryin eluates and sera from renal transplant recipients with chronic allograft nephropathy", Transplantation, 76, pp.395~400 (2003)
- Scornik JC, "Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction", Am J Transplant, 7, pp.1808~1814 (2007)
- Dragun D, "Role of non-HLA antibodies in organ transplantation", Curr Opin Organ Transplant, 17, pp.440~445 (2012)
- Schindler R, "Hypertension increases expression of growth factors and MHC II in chronic allograft nephropathy", Kidney Int, 63, pp.2302~2308 (2003)